- This topic has 1 voice and 0 replies.
Viewing 0 reply threads
-
Posts
-
-
In this column, Reid D’Amico shares background on an investigational CF therapy called SPX-101, developed by Spyryx Biosciences, which has shown promise in early animal studies. Click here to read more from Reid.
What did you think of this column?
-
Viewing 0 reply threads
- You must be logged in to reply to this topic.
